Search BIOE
Bio Essence Corp
OTC · CIK 1723059
Last close0.18
Daily change+0.00 (0.00%)
10 Years gain-59.56%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BIOE · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
65.5Momentum
n/aAcceleration
n/aConfidence
78.0Annual Revenue6
Quarterly Revenue19
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality22.1 / 25
Capital Efficiency15.1 / 20
Balance Sheet0.1 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 19.6984 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM377.37%OK
Revenue CAGR 3Y45.07%OK
Gross Margin62.32%OK
Operating Margin33.74%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y205.09%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.90M | $1.43M | $900,011.00 | $1.57M | n/a | 75.28% | 47.43% | n/a | n/a | 38.01M |
| 2025 FY Dec 31, 2024 | $323,940.00 | $217,077.00 | -$459,438.00 | $623,865.00 | n/a | 67.01% | -141.83% | n/a | n/a | 38.01M |
| 2024 FY Dec 31, 2023 | n/a | $0.00 | -$345,590.00 | -$1.03M | -$1.03M | n/a | n/a | n/a | n/a | n/a |
| 2023 FY Dec 31, 2023 | $551,506.00 | $277,446.00 | n/a | n/a | n/a | 50.31% | n/a | n/a | n/a | 35.95M |
| 2023 FY Dec 31, 2022 | $621,590.00 | $328,326.00 | -$511,138.00 | -$703,241.00 | -$706,983.00 | 52.82% | -82.23% | -113.74% | n/a | 33.01M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.69M | sum latest 4 fiscal quarters Revenue | OK | 0001213900-26-090174, 0001213900-25-108357 |
| Revenue Growth TTM | 377.37% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001213900-26-090174, 0001213900-25-108357 |
| Revenue CAGR 3Y | 45.07% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001213900-26-035467 |
| Revenue CAGR 5Y | 14.63% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001213900-26-035467 |
| Gross Profit CAGR 3Y | 63.25% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001213900-26-035467 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001213900-26-090174, 0001213900-25-108357 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 62.32% | Gross Profit / Revenue | OK | 0001213900-26-090174, 0001213900-25-108357 |
| Operating Margin | 33.74% | Operating Income / Revenue | OK | 0001213900-26-090174, 0001213900-25-108357 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001213900-26-090174 |
| Current Ratio | 0.38x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.01x | (Cash + Short-term Investments) / Total Debt | OK | 0001213900-26-090174 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001213900-26-035467 |